close and back to page

Latest News

Latest News

Abbott Launches First and Only Smartphone Compatible Insertable Cardiac Monitor in U.S.

Physicians can remotely monitor their patients with Confirm Rx for even the most difficult to detect cardiac arrhythmias, including irregular heartbeats.

Abbott (No. 10 on the DiversityInc Top 50 Companies list ) has secured U.S. Food and Drug Administration (FDA) clearance for the Confirm Rx Insertable Cardiac Monitor (ICM), the world's first and only smartphone compatible ICM designed to help physicians remotely identify cardiac arrhythmias. With FDA clearance Abbott can now provide U.S. patients a new way to monitor for abnormal heart rhythms while staying connected to their physician remotely and being able to engage in their health care.


An arrhythmia is an abnormal heart rhythm that develops when disease or injury disrupts the heart's electrical signals, causing the heart to beat erratically. As the heart begins to beat too fast or too slow, changes in blood flow can expose patients to symptoms such as palpitations, dizziness, shortness of breath or fainting.

"Confirm Rx shows what we can do with cutting edge communication technology and the most advanced medical devices that provide new opportunities to improve patient care," said Avi Fischer, M.D., divisional vice president and medical director of Abbott's Cardiac Rhythm Management business. "By offering a device that uses Bluetooth wireless technology from the patient's smartphone, we can help physicians easily and remotely diagnose potentially dangerous abnormal heart beats without requiring the patient to use a separate or cumbersome recording device."

Abbott's insertable cardiac monitors have helped advance how physicians remotely monitor patients for abnormal heart rhythms. By incorporating Bluetooth® wireless technology, Abbott has advanced remote monitoring by allowing patients to connect their ICM to their smartphone via the myMerlin mobile app. Once implanted—just under the skin in the chest during a quick, minimally-invasive outpatient procedure—Confirm Rx continuously monitors heart rhythms to detect a range of cardiac arrhythmias, including irregular heartbeats, or atrial fibrillation.

Data collected by the device is then securely transmitted to a patient's physician via the mobile app on a schedule set by the clinic. The app also allows patients to record symptomatic events from their own smartphone without the need for additional hardware such as handheld activators or bedside transmitters.

The Benefits of the Confirm Rx ICM

The Confirm Rx ICM is the world's first insertable cardiac monitor that combines a quick and minimally invasive procedure with a device that uses Bluetooth wireless technology, allowing patients to connect using a mobile app downloaded to their own smartphone. The device and mobile app are designed to allow for:

  • Continuous heart monitoring using the patient's smartphone to record episodes of irregular heartbeat.
  • The ability for patients to easily send their heart rhythm information to their doctor without interrupting daily activities.
  • A discreet implant—the slimmest insertable cardiac monitor available today.

While the Confirm Rx ICM continuously monitors for abnormal heart rhythms and transmits data to a patient's physician, the myMerlin app also allows patients to track symptoms proactively, sync their data with their clinic at any time, and view their transmission history without having to contact their clinic to confirm successful data transfers.

The Confirm Rx ICM limits communication to a single authenticated myMerlin mobile app. The Confirm Rx ICM and the myMerlin mobile app encrypt all wireless communications using the highest standards in mobile security.

Abbott: Top Internship for Healthcare and Tech

Interns have spoken: Abbott is the top college internship program for healthcare and tech & engineering.

Originally Published by Abbott.

Abbott recognizes the need to develop its future leaders early, and has been named the top healthcare and tech & engineering internship program by Vault.

Read More Show Less

New Study Shows Abbott's Novel Diagnostic Test Could Help Rule Out Heart Attacks Earlier

Preliminary research indicates that a diagnostic test currently in development, that is done at the patient's side in minutes, has similar accuracy to a high-sensitive troponin test for early rule out of a heart attack .

Originally Published by Abbott.

For someone experiencing cardiac symptoms in the emergency room, every minute matters as physicians determine whether someone is having a heart attack. New data, published online in JAMA Cardiology, found a new blood test under development that is done right at the patient's side in as little as 15 minutes could identify nearly three-fifths (56.7 percent) of people at low-risk of experiencing a heart attack, similar to the results of a High Sensitive Troponin-I blood test done in the laboratory setting.

Read More Show Less

Abbott: Partnering for a Healthier Future

Abbott supports the First Ladies of Africa in the fight to end AIDS in children and keep mothers healthy.

Originally Published by Abbott.

In countries around the world, Abbott is working across its businesses and in partnerships with others to create healthier futures for families. One example: since 2014, Abbott's diagnostics business has supported the work of the Organization of African First Ladies Against HIV/AIDS (OAFLA – pictured above) to fight the AIDS epidemic in Africa, particularly among pregnant women and children – who are among the most vulnerable populations impacted by the disease.

At an OAFLA meeting on the sidelines of the UN General Assembly in New York City, Abbott and several other organizations are being recognized by OAFLA for longstanding partnership and support, including public-private partnerships that bring together technical, financial and other resources to focus on a global health challenge such as HIV/AIDS.

Read More Show Less

Abbott: DRG Stimulator, A Life Changing Technology for Chronic Pain.

The new technological DRG therapy may be the key to easing daily tasks for those with chronic pain.

Originally Published by Abbott.

Living with chronic pain affects not just your body but also your mind. It can make getting around and getting along equally difficult.

But with innovation in health technology comes hope. Abbott has developed a new device found to be more effective than traditional therapy at relieving chronic pain.

Read More Show Less

Abbott: Expediting Blood Testing With i-Stat

The portable, handheld i-STAT Alinity delivers quick blood test results anywhere you are.

Originally Published by Abbott.

Every day, countless blood samples are tested all around the world for one purpose: to help diagnose and treat medical conditions. From the couple eagerly awaiting the results of a pregnancy blood test to a worried cancer patient hoping for more answers, diagnostic blood tests give vital insight into what's happening underneath the skin.

Read More Show Less

Abbott: Freestyle Libre 14 Day, Now FDA Approved

Abbott's flash glucose monitor now FDA-approved for two weeks of use in U.S. between sensor changes.

Originally Published by Abbott.

The U.S. Food and Drug Administration has approved FreeStyle Libre 14 day— Abbott's revolutionary continuous glucose monitoring system. In the U.S., you can wear the sensor up to 14 days with high accuracy.

Read More Show Less

At Abbott, You Look Like An Engineer

Decades before #ILookLikeAnEngineer, Abbott paved the way for a non-profit dedicated to diversity in STEM.

Originally Published by Abbott.

#ILookLikeAnEngineer.

Remember this? A few years ago, a young software engineer was featured in a recruiting advertisement, only to be accused of not being an actual engineer. Frustrated with the assertion, Isis Wenger started a movement to break the stereotype of what an engineer should look like.

Read More Show Less

Abbott Receives FDA Approval for Next-Generation MitraClip Device to Treat People with Leaky Heart Valves

MitraClip is the gold-standard minimally invasive alternative to open-heart surgery for people needing mitral valve repair.

Originally Published by Abbott.

Abbott announced it received approval from the U.S. Food and Drug Administration (FDA) for a next-generation version of its leading MitraClip® heart valve repair device used to repair a leaky mitral valve without open-heart surgery. The transcatheter clip-based therapy, now on a third generation of product innovations, has been used to treat more than 65,000 patients worldwide over the last ten years.

Read More Show Less